Source link : https://www.newshealth.biz/health-news/fda-staff-not-quite-sold-on-sotagliflozin-for-t1d-patients-with-ckd/
FDA staff raised familiar safety concerns about sotagliflozin as a treatment for type 1 diabetes (T1D) as the agency again considers an approval, though now for just a subset with chronic kidney disease (CKD). On Thursday, members of the Endocrinologic and Metabolic Drugs Advisory Committee will help the FDA decide whether the available data support […]
Author : News Health
Publish date : 2024-10-30 21:33:52
Copyright for syndicated content belongs to the linked Source.
